retatrutide glp-1 gip glucagon receptor agonist triple Agonism Based Therapies for Obesity Beyond GLP-1: Retatrutide's triple-agonist mechanism

Ethics declarations Competing interests The author declares associations with the following companies: Astra-Zeneca, Bristol-Myers Squibb, Merck Sharpe & Dohme, NovoNordisk and Sanofi-Aventis (advisory board membership

Energy levels may dip temporarily as caloric intake drops, which is why fatigue management matters

How stable is Retatrutide in storage

Key points Cardiovascular outcome trials in individuals with type 2 diabetes mellitus demonstrate that glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists reduce the rates of non-fatal myocardial infarction, non-fatal stroke and cardiovascular death

Dose adjustments to those medications may be needed as retatrutide improves insulin sensitivity